Clinical Trial

Test-retest Evaluation of [18F]F-AraG PET

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 24, 2024 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This pilot study aims to evaluate the test-retest variability of \[18F\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \[18F\]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two \[18F\]F-AraG PET/CT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-10.
Status change: Not Yet Recruiting → Recruiting 2024-10-22
Trial Details
NCT Number NCT06084806
Lead Sponsor CellSight Technologies, Inc.
Collaborators: University of Iowa
Conditions Non-small Cell Lung Cancer
Enrollment 10 participants
Start Date 2023-10-31
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-24